Inaedis
Our company aims to disrupt the cold chain logistics by addressing the unmet need of thermal stabilization of heat and freeze-sensitive vaccines and biologics at room temperature. We provide thermal stabilization by converting liquid biologics into room-temperature stable powder by using our proprietary Rapid Room-Temperature Dehydration Technology (RTAD)
Latest News:
A note of thanks
PRINCETON, NEW JERSEY (April 24, 2023) — We are grateful to Prof. John Carpenter for reviewing our study, “Rapid Room-Temperature Aerosol Dehydration Versus Spray Drying: A Novel Paradigm in Biopharmaceutical Drying Technologies,” published in the Journal of Pharmaceutical Sciences. Prof. Carpenter is Professor Emeritus of Pharmaceutical Sciences at the University of Colorado School of Pharmacy, and…
Inaedis receives $150,000 in non-dilutive funding from the Catalyst Seed R&D Grant Program
New Jersey program helps life sciences therapeutics companies commercialize. PRINCETON, NEW JERSEY (March 20, 2024) — Inaedis, Inc., new platform biotechnology company, was awarded $150,000 in non-dilutive funding from the Catalyst Seed R&D Grant Program, a state-led initiative to support deep biotechnology ventures in New Jersey. Catalyst is led by the New Jersey Commission on…
Inaedis announces investment from Roadrunner Venture Studios
Deep tech venture studio joins Princeton Innovation Center in supporting powderized vaccine company. PRINCETON, NEW JERSEY (February 27, 2024) — Inaedis, Inc., a new platform biotechnology company, closed a pre-seed investment from Roadrunner Venture Studios, the premier deep tech venture studio in the United States. The investment will allow the company to continue to develop…